Meeting
2019 Genitourinary Cancers Symposium
Efficacy of abiraterone and enzalutamide in patients who had disease progression within twelve months of completing docetaxel for metastatic castration sensitive prostate cancer.
Authors
Gang Chen
NCI/NIH, Bethesda, MD
Gang Chen , David James VanderWeele , Fatima Karzai , Marijo Bilusic , Munjid Al Harthy , Philip M. Arlen , Inger L. Rosner , Guinevere Chun , Helen Owens , Anna Couvillon , Amy Hankin , Monique Williams , Lisa M. Cordes , William Douglas Figg , James L. Gulley , William L. Dahut , Ravi Amrit Madan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer,Prostate Cancer
Sub Track
Prostate Cancer - Advanced Disease
Clinical Trial Registration Number
NCT02649855
Citation
J Clin Oncol 37, 2019 (suppl 7S; abstr 241)
DOI
10.1200/JCO.2019.37.7_suppl.241
Abstract #
241
Poster Bd #
K20
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
The efficacy and safety of tinengotinib in patients with heavily pretreated metastatic castration-resistant prostate cancer (mCRPC).
First Author: Guo Hongqian
Poster
2022 ASCO Genitourinary Cancers Symposium
Treatment outcomes for metastatic castration-resistant prostate cancer (mCRPC) following progression on upfront androgen deprivation therapy (ADT) with androgen receptor pathway inhibitors (ARPI) for metastatic castration-sensitive prostate cancer (mCSPC).
First Author: Daniel Joseph Khalaf
Poster
2021 Genitourinary Cancers Symposium
Multi-institutional evaluation of the clinical outcomes and genomic correlates of African Americans with metastatic castration-sensitive prostate cancer (mCSPC).
First Author: Meredith MI Freeman
Poster
2015 Genitourinary Cancers Symposium
AR splice variant 7 (AR-V7) and response to taxanes in men with metastatic castration-resistant prostate cancer (mCRPC).
First Author: Emmanuel S. Antonarakis